TY - JOUR
T1 - The Innate Immune Receptor NLRX1 Functions as a Tumor Suppressor by Reducing Colon Tumorigenesis and Key Tumor-Promoting Signals
AU - Koblansky, A. Alicia
AU - Truax, Agnieszka D.
AU - Liu, Rongrong
AU - Montgomery, Stephanie A.
AU - Ding, Shengli
AU - Wilson, Justin E.
AU - Brickey, W. June
AU - Mühlbauer, Marcus
AU - McFadden, Rita Marie T.
AU - Hu, Peizhen
AU - Li, Zengshan
AU - Jobin, Christian
AU - Lund, Pauline Kay
AU - Ting, Jenny P.Y.
N1 - Publisher Copyright:
© 2016 The Authors.
PY - 2016/3/22
Y1 - 2016/3/22
N2 - NOD-like receptor (NLR) proteins are intracellular innate immune sensors/receptors that regulate immunity. This work shows that NLRX1 serves as a tumor suppressor in colitis-associated cancer (CAC) and sporadic colon cancer by keeping key tumor promoting pathways in check. Nlrx1-/- mice were highly susceptible to CAC, showing increases in key cancer-promoting pathways including nuclear factor κB (NF-κB), mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription 3 (STAT3), and interleukin 6 (IL-6). The tumor-suppressive function of NLRX1 originated primarily from the non-hematopoietic compartment. This prompted an analysis of NLRX1 function in the Apcmin/+ genetic model of sporadic gastrointestinal cancer. NLRX1 attenuated Apcmin/+ colon tumorigenesis, cellular proliferation, NF-κB, MAPK, STAT3 activation, and IL-6 levels. Application of anti-interleukin 6 receptor (IL6R) antibody therapy reduced tumor burden, increased survival, and reduced STAT3 activation in Nlrx1-/-Apcmin/+ mice. As an important clinical correlate, human colon cancer samples expressed lower levels of NLRX1 than healthy controls in multiple patient cohorts. These data implicate anti-IL6R as a potential personalized therapy for colon cancers with reduced NLRX1.
AB - NOD-like receptor (NLR) proteins are intracellular innate immune sensors/receptors that regulate immunity. This work shows that NLRX1 serves as a tumor suppressor in colitis-associated cancer (CAC) and sporadic colon cancer by keeping key tumor promoting pathways in check. Nlrx1-/- mice were highly susceptible to CAC, showing increases in key cancer-promoting pathways including nuclear factor κB (NF-κB), mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription 3 (STAT3), and interleukin 6 (IL-6). The tumor-suppressive function of NLRX1 originated primarily from the non-hematopoietic compartment. This prompted an analysis of NLRX1 function in the Apcmin/+ genetic model of sporadic gastrointestinal cancer. NLRX1 attenuated Apcmin/+ colon tumorigenesis, cellular proliferation, NF-κB, MAPK, STAT3 activation, and IL-6 levels. Application of anti-interleukin 6 receptor (IL6R) antibody therapy reduced tumor burden, increased survival, and reduced STAT3 activation in Nlrx1-/-Apcmin/+ mice. As an important clinical correlate, human colon cancer samples expressed lower levels of NLRX1 than healthy controls in multiple patient cohorts. These data implicate anti-IL6R as a potential personalized therapy for colon cancers with reduced NLRX1.
UR - http://www.scopus.com/inward/record.url?scp=84962543071&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962543071&partnerID=8YFLogxK
U2 - 10.1016/j.celrep.2016.02.064
DO - 10.1016/j.celrep.2016.02.064
M3 - Article
C2 - 26971998
AN - SCOPUS:84962543071
SN - 2211-1247
VL - 14
SP - 2562
EP - 2575
JO - Cell Reports
JF - Cell Reports
IS - 11
ER -